Clozapine's REMS Program Officially Over

(MEDPAGE today) – FDA (FDA) has officially canceled a program to evaluate a strategy and reduce risk in Kluzapin (Rems), with all ReMS operations stopped from June 13. The announcement comes several months after a joint consulting committee …